Compare STHO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STHO | OVID |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.6M | 117.5M |
| IPO Year | 2022 | 2017 |
| Metric | STHO | OVID |
|---|---|---|
| Price | $8.05 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.40 |
| AVG Volume (30 Days) | 29.9K | ★ 1.5M |
| Earning Date | 05-20-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.73 | 3.90 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,143,000.00 | $566,000.00 |
| Revenue This Year | N/A | $1,077.56 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.06 | $0.24 |
| 52 Week High | $9.24 | $2.38 |
| Indicator | STHO | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 40.42 | 67.31 |
| Support Level | $7.72 | $1.43 |
| Resistance Level | $8.09 | $2.01 |
| Average True Range (ATR) | 0.24 | 0.15 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 9.09 | 60.11 |
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties and land and development properties.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.